Human Papillomavirus Infection and Cervical Cancer in HIV+ Women

Part of the Cancer Treatment and Research book series (CTAR, volume 177)


Human papillomavirus (HPV) is the first identified necessary cause of human cancers and is associated with nearly 100% of all cervical cancers. Compared to the general female populations, HIV+ women have higher prevalence and incidence of cervical HPV infections, higher risks of persistent HPV infections and subsequent cervical intraepithelial lesions, and a higher incidence of cervical cancer. Although the wide use of combined antiretroviral therapy (cART) has improved the immune function and the longevity of HIV+ women, the incidence of cervical cancer in HIV+ women has not declined. For HIV+ women who follow routine cervical cancer screenings, their incidence of cervical cancer is comparable to that in HIV-negative women. Thus, adherence to the recommended cervical cancer screening is still critical for HIV+ women to prevent cervical cancer. Prophylactic HPV vaccines may also benefit HIV+ women, but prospective studies are needed to determine the effectiveness of HPV vaccination on reducing cervical cancer incidence in HIV+ women.


  1. 1.
    Zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92(9):690–8CrossRefPubMedGoogle Scholar
  2. 2.
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55(4):244–265CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Munoz N, Castellsague X, de Gonzalez AB, Gissmann L (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine, 24 (3):1–10CrossRefGoogle Scholar
  4. 4.
    Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR et al (2012) The biology and life-cycle of human papillomaviruses. Vaccine 30(Suppl 5):F55–F70CrossRefPubMedGoogle Scholar
  5. 5.
    de Sanjose S, Brotons M, Pavon MA (2017) The natural history of human papillomavirus infection. Best Practice & Research Clinical Obstetrics & GynaecologyGoogle Scholar
  6. 6.
    Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401(1):70–79CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Humans IWGotEoCRt (1995) Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans. 64(1)Google Scholar
  8. 8.
    de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13(6):607–615CrossRefPubMedGoogle Scholar
  9. 9.
    Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT et al (2012) Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 30(Suppl 5):F24–F33CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–3044CrossRefPubMedGoogle Scholar
  12. 12.
    Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine. 24 (3):11–25CrossRefGoogle Scholar
  13. 13.
    Castellsagué SdS X, Aguado T, Louie KS, Bruni L, Muñoz J, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer SB E, Bosch FX (2007) HPV and cervical cancer in the world. 2007 report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). World Health OrganizationGoogle Scholar
  14. 14.
    de Martel C, Plummer M, Vignat J, Franceschi S (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141(4):664–670CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chow LT, Broker TR, Steinberg BM (2010) The natural history of human papillomavirus infections of the mucosal epithelia. APMIS. 118(6–7):422–449CrossRefPubMedGoogle Scholar
  16. 16.
    Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D (2007) 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 11(4):201–222CrossRefPubMedGoogle Scholar
  17. 17.
    Castellsague X, Pawlita M, Roura E, Margall N, Waterboer T, Bosch FX et al (2014) Prospective seroepidemiologic study on the role of human papillomavirus and other infections in cervical carcinogenesis: evidence from the EPIC cohort. Int J Cancer 135(2):440–452CrossRefPubMedGoogle Scholar
  18. 18.
    Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N et al (2014) Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. Int J Cancer 135(2):453–466CrossRefPubMedGoogle Scholar
  19. 19.
    Roura E, Travier N, Waterboer T, de Sanjose S, Bosch FX, Pawlita M et al (2016) The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC Cohort. PLoS ONE 11(1):e0147029CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Castellsague X, Bosch FX, Munoz N (2002) Environmental co-factors in HPV carcinogenesis. Virus Res 89(2):191–199CrossRefPubMedGoogle Scholar
  21. 21.
    Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P et al (2013) An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45(9):970–976CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefGoogle Scholar
  23. 23.
    World Health Organization. Number of people (all ages) living with HIV estimates by country 2017. Available from:
  24. 24.
    Centers for Disease Control and Prevention (2012) Human papillomavirus-associated cancers—United States, 2004-2008. MMWR Morb Mortal Wkly Rep 61:258–261Google Scholar
  25. 25.
    Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE (2012) Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 30(42):6016–6019CrossRefPubMedGoogle Scholar
  26. 26.
    Cates W Jr (1999) Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American social health association panel. Sex Transm Dis 26(4):S2–S7CrossRefPubMedGoogle Scholar
  27. 27.
    Dunne EF, Markowitz LE (2006) Genital human papillomavirus infection. Clin Infect Dis 43(5):624–629CrossRefPubMedGoogle Scholar
  28. 28.
    Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC et al (2013) Sexually transmitted infections among US Women and Men: prevalence and incidence estimates, 2008. Sex Transm Dis 40(3):187–193CrossRefPubMedGoogle Scholar
  29. 29.
    Vinodhini K, Shanmughapriya S, Das BC, Natarajaseenivasan K (2012) Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstet 285(3):771–777CrossRefPubMedGoogle Scholar
  30. 30.
    de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N et al (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 7(7):453–459CrossRefPubMedGoogle Scholar
  31. 31.
    Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16–S24CrossRefPubMedGoogle Scholar
  32. 32.
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338(7):423–428CrossRefPubMedGoogle Scholar
  33. 33.
    Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E et al (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285(23):2995–3002CrossRefPubMedGoogle Scholar
  34. 34.
    Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA (2003) Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157(3):218–226CrossRefPubMedGoogle Scholar
  35. 35.
    Rodriguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME et al (2010) Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 102(5):315–324CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S et al (2011) Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20(4):699–707CrossRefPubMedGoogle Scholar
  37. 37.
    Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE (2012) Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 72(23):6183–6190CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Winer RL, Hughes JP, Feng Q, Stern JE, Xi LF, Koutsky LA (2016) Incident Detection of high-risk human papillomavirus infections in a cohort of high-risk women aged 25–65 Years. J Infect Dis 214(5):665–675CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S et al (2011) Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003–2006. J Infect Dis 204(4):566–573CrossRefPubMedGoogle Scholar
  40. 40.
    Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K et al (2000) Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 283(8):1031–1037CrossRefGoogle Scholar
  41. 41.
    Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A et al (2005) Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97(6):425–432CrossRefPubMedGoogle Scholar
  42. 42.
    De Vuyst H, Lillo F, Broutet N, Smith JS (2008) HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur. J. Cancer Prev. official J European Cancer Prevention Organisation (ECP). 17(6):545–554CrossRefGoogle Scholar
  43. 43.
    Denslow SA, Rositch AF, Firnhaber C, Ting J, Smith JS (2014) Incidence and progression of cervical lesions in women with HIV: a systematic global review. Int J STD AIDS 25(3):163–177CrossRefPubMedGoogle Scholar
  44. 44.
    Thorsteinsson K, Ladelund S, Jensen-Fangel S, Katzenstein TL, Johansen IS, Pedersen G et al (2016) Incidence of cervical dysplasia and cervical cancer in women living with HIV in Denmark: comparison with the general population. HIV Med. 17(1):7–17CrossRefPubMedGoogle Scholar
  45. 45.
    Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT et al (2007) Cohort profile: the North American AIDS cohort collaboration on research and design (NA-ACCORD). Int J Epidemiol 36(2):294–301CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Smith D, The HIV (1998) Epidemiology research study, HIV out-patient study, and the spectrum of disease studies. J Acquir Immune Defic Syndr Hum Retrovirol. 17(Suppl 1):S17–S19CrossRefPubMedGoogle Scholar
  47. 47.
    Jaen A, Casabona J, Esteve A, Miro JM, Tural C, Ferrer E et al ( 2005) [Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Medicina clinica.124(14):525–31Google Scholar
  48. 48.
    Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 10(12):1152–1159CrossRefPubMedGoogle Scholar
  49. 49.
    Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr (1997) Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337(19):1343–1349CrossRefGoogle Scholar
  50. 50.
    Kitchener H, Nelson L, Adams J, Mesher D, Sasieni P, Cubie H et al (2007) Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 121(11):2484–2491CrossRefPubMedGoogle Scholar
  51. 51.
    Vernon SD, Holmes KK, Reeves WC (1995) Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Clin Infect Dis 21(Suppl 1):S121–S124CrossRefPubMedGoogle Scholar
  52. 52.
    Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P et al (1999) Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 91(3):226–236CrossRefPubMedGoogle Scholar
  53. 53.
    Del Mistro A, Bonaldi L, Bertorelle R, Minucci D, Franzetti M, Cattelan A et al (2001) Genital human papillomavirus types in immunocompetent and immunodepressed women in Northeast Italy: prevalence and cytomorphological correlations. J Low Genit Tract Dis. 5(1):12–20PubMedGoogle Scholar
  54. 54.
    de Sanjose S, Palefsky J (2002) Cervical and anal HPV infections in HIV positive women and men. Virus Res 89(2):201–211CrossRefPubMedGoogle Scholar
  55. 55.
    Hessol NA, Seaberg EC, Preston-Martin S, Massad LS, Sacks HS, Silver S et al (2004) Cancer risk among participants in the women’s interagency HIV study. J Acquir Immune Defic Syndr 36(4):978–985CrossRefPubMedGoogle Scholar
  56. 56.
    Strickler HD, Burk RD, Fazzari M, Anastos K, Minkoff H, Massad LS et al (2005) Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 97(8):577–586CrossRefPubMedGoogle Scholar
  57. 57.
    Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC et al (2006) Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester. New York. J Infect Dis. 194(4):428–434CrossRefPubMedGoogle Scholar
  58. 58.
    Jong E, Mulder JW, van Gorp EC, Wagenaar JK, Derksen J, Westerga J et al (2008) The prevalence of human papillomavirus (HPV) infection in paired urine and cervical smear samples of HIV-infected women. J Clin Virol 41(2):111–115CrossRefPubMedGoogle Scholar
  59. 59.
    Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR (2009) Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 51(3):274–282CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Grinsztejn B, Veloso VG, Levi JE, Velasque L, Luz PM, Friedman RK et al (2009) Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women. Int J Infect Dis. 13(1):72–80CrossRefPubMedGoogle Scholar
  61. 61.
    Kojic EM, Cu-Uvin S, Conley L, Bush T, Onyekwuluje J, Swan DC, et al (2010) Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (The SUN study). Sex Transm DisGoogle Scholar
  62. 62.
    Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, et al (2012) Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. J Acquir Immune Defic SyndrGoogle Scholar
  63. 63.
    Hessol NA, Holly EA, Efird JT, Minkoff H, Weber KM, Darragh TM et al (2013) Concomitant anal and cervical human papillomavirusV infections and intraepithelial neoplasia in HIV-infected and uninfected women. AIDS 27(11):1743–1751CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Ebrahim S, Mndende XK, Kharsany AB, Mbulawa ZZ, Naranbhai V, Frohlich J et al (2016) High burden of human papillomavirus (HPV) infection among young women in KwaZulu-Natal, South Africa. PLoS ONE 11(1):e0146603CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Clifford GM, Goncalves MA, Franceschi S (2006) Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20(18):2337–2344CrossRefPubMedGoogle Scholar
  66. 66.
    Park LS, Hernandez-Ramirez RU, Silverberg MJ, Crothers K, Dubrow R (2016) Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. Aids 30(2):273–291CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Hankins C, Coutlee F, Lapointe N, Simard P, Tran T, Samson J, et al (1999) Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women’s HIV Study Group. CMAJ: Canadian Medical Association journal = journal de l’Association medicale canadienne 160(2):185–91Google Scholar
  68. 68.
    Minkoff H, Feldman JG, Strickler HD, Watts DH, Bacon MC, Levine A et al (2004) Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis 189(10):1821–1828CrossRefPubMedGoogle Scholar
  69. 69.
    Sinayobye J, Sklar M, Hoover DR, Shi Q, Dusingize JC, Cohen M et al (2014) Prevalence and risk factors for high-risk human papillomavirus (hrHPV) infection among HIV-infected and uninfected Rwandan women: implications for hrHPV-based screening in Rwanda. Infect Agent Cancer. 9:40CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Massad L, Keller M, Xie X, Minkoff H, Palefsky J, D’Souza G et al (2016) Multitype infections with human papillomavirus: impact of human immunodeficiency virus coinfection. Sex Transm Dis 43(10):637–641CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Thorsteinsson K, Storgaard M, Katzenstein TL, Ladelund S, Ronsholt FF, Johansen IS et al (2016) Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark— the SHADE. BMC Cancer 16(1):866CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS et al (2007) Prevalence of HPV infection among females in the United States. JAMA 297(8):813–819CrossRefPubMedGoogle Scholar
  73. 73.
    McKenzie ND, Kobetz EN, Hnatyszyn J, Twiggs LB, Lucci JA 3rd (2010) Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. Gynecol Oncol 116(3):572–577CrossRefPubMedGoogle Scholar
  74. 74.
    Massad LS, Xie X, Burk RD, D’Souza G, Darragh TM, Minkoff H et al (2016) Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Am J Obstet Gynecol 214(3):354.e1–354.e6CrossRefGoogle Scholar
  75. 75.
    Levi JE, Kleter B, Quint WG, Fink MC, Canto CL, Matsubara R et al (2002) High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol 40(9):3341–3345CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Levi JE, Fernandes S, Tateno AF, Motta E, Lima LP, Eluf-Neto J et al (2004) Presence of multiple human papillomavirus types in cervical samples from HIV-infected women. Gynecol Oncol 92(1):225–231CrossRefPubMedGoogle Scholar
  77. 77.
    Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, Kissinger PJ et al (2005) Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomark Prev 14(10):2439–2445CrossRefGoogle Scholar
  78. 78.
    Adebamowo SN, Olawande O, Famooto A, Dareng EO, Offiong R, Adebamowo CA (2017) Persistent low-risk and high-risk human papillomavirus infections of the uterine cervix in HIV-negative and HIV-positive women. Front. publ. health. 5:178CrossRefGoogle Scholar
  79. 79.
    Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A et al (2001) Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 184(6):682–690CrossRefGoogle Scholar
  80. 80.
    Massad LS, Xie X, Burk R, Keller MJ, Minkoff H, D’Souza G et al (2014) Long-term cumulative detection of human papillomavirus among HIV seropositive women. Aids 28(17):2601–2608CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Branca M, Garbuglia AR, Benedetto A, Cappiello T, Leoncini L, Migliore G et al (2003) Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up. Int J STD AIDS 14(6):417–425CrossRefPubMedGoogle Scholar
  82. 82.
    Whitham HK, Hawes SE, Chu H, Oakes JM, Lifson AR, Kiviat NB et al (2017) A comparison of the natural history of HPV infection and cervical abnormalities among HIV-positive and HIV-negative women in Senegal. Africa. Cancer Epidemiol Biomarkers Prev. 26(6):886–894CrossRefPubMedGoogle Scholar
  83. 83.
    Travassos AG, Netto E, Xavier-Souza E, Nobrega I, Adami K, Timbo M et al (2017) Predictors of HPV incidence and clearance in a cohort of Brazilian HIV-infected women. PLoS ONE 12(10):e0185423CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Nappi L, Carriero C, Bettocchi S, Herrero J, Vimercati A, Putignano G (2005) Cervical squamous intraepithelial lesions of low-grade in HIV-infected women: recurrence, persistence, and progression, in treated and untreated women. Eur J Obstet Gynecol Reprod Biol 121(2):226–232CrossRefPubMedGoogle Scholar
  85. 85.
    D’Souza G, Fakhry C, Sugar EA, Seaberg EC, Weber K, Minkoff HL et al (2007) Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 121(1):143–150CrossRefPubMedGoogle Scholar
  86. 86.
    Gingelmaier A, Grubert T, Kaestner R, Mylonas I, Weissenbacher T, Bergauer F et al (2007) High recurrence rate of cervical dysplasia and persistence of HPV infection in HIV-1-infected women. Anticancer Res 27(4A):1795–1798PubMedGoogle Scholar
  87. 87.
    Fontaine J, Hankins C, Money D, Rachlis A, Pourreaux K, Ferenczy A et al (2008) Human papillomavirus type 16 (HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV. J Clin Virol 43(3):307–312CrossRefPubMedGoogle Scholar
  88. 88.
    Kjaer SK, Frederiksen K, Munk C, Iftner T (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102(19):1478–1488CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Piketty C, Kazatchkine MD (2005) Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr HIV/AIDS Rep. 2(3):140–145CrossRefPubMedGoogle Scholar
  90. 90.
    Denny L, Boa R, Williamson AL, Allan B, Hardie D, Stan R et al (2008) Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 111(6):1380–1387CrossRefPubMedGoogle Scholar
  91. 91.
    Massad LS, Riester KA, Anastos KM, Fruchter RG, Palefsky JM, Burk RD, et al (1999) Prevalence and predictors of squamous cell abnormalities in Papanicolaou smears from women infected with HIV-1. Women’s Interagency HIV Study Group. J Acquir Immune Defic Syndr. 1999;21(1):33–41PubMedGoogle Scholar
  92. 92.
    Massad LS, Seaberg EC, Watts DH, Hessol NA, Melnick S, Bitterman P et al (2004) Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. Aids. 18(1):109–113CrossRefPubMedGoogle Scholar
  93. 93.
    Yamada R, Sasagawa T, Kirumbi LW, Kingoro A, Karanja DK, Kiptoo M et al (2008) Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. J Med Virol 80(5):847–855CrossRefPubMedGoogle Scholar
  94. 94.
    Cardillo M, Hagan R, Abadi J, Abadi MA (2001) CD4 T-cell count, viral load, and squamous intraepithelial lesions in women infected with the human immunodeficiency virus. Cancer 93(2):111–114CrossRefPubMedGoogle Scholar
  95. 95.
    Minkoff H, Zhong Y, Burk RD, Palefsky JM, Xue X, Watts DH et al (2010) Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 201(5):681–690CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Clifford GM, Franceschi S, Keiser O, Schoni-Affolter F, Lise M, Dehler S et al (2016) Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: a nested case-control study in the Swiss HIV cohort study. Int J Cancer 138(7):1732–1740CrossRefPubMedGoogle Scholar
  97. 97.
    Rousseau MN, Costes V, Konate I, Nagot N, Foulongne V, Ouedraogo A et al (2007) Viral load and genomic integration of HPV 16 in cervical samples from HIV-1-infected and uninfected women in Burkina Faso. J Med Virol 79(6):766–770CrossRefPubMedGoogle Scholar
  98. 98.
    Centers for Disease Control and Prevention (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 41(Rr-17):1–19Google Scholar
  99. 99.
    Schneider MF, Gange SJ, Williams CM, Anastos K, Greenblatt RM, Kingsley L et al (2005) Patterns of the hazard of death after AIDS through the evolution of antiretroviral therapy: 1984-2004. AIDS (London, England). 19(17):2009–2018CrossRefGoogle Scholar
  100. 100.
    Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al (2007) HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defic. Syndr. (1999) 46(1):72–7Google Scholar
  101. 101.
    Antiretroviral Therapy Cohort Collaboration (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 372(9635):293–9Google Scholar
  102. 102.
    Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC et al (2008) Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300(1):51–59CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C et al (2010) The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24(1):123–137CrossRefPubMedGoogle Scholar
  104. 104.
    Calabresi A, Ferraresi A, Festa A, Scarcella C, Donato F, Vassallo F et al (2013) Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Med. 14(8):481–490CrossRefPubMedGoogle Scholar
  105. 105.
    International Collaboration on HIV and Cancer (2000) Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92(22):1823–1830CrossRefGoogle Scholar
  106. 106.
    Bonnet F, Chene G (2008) Evolving epidemiology of malignancies in HIV. Curr Opin Oncol 20(5):534–540CrossRefPubMedGoogle Scholar
  107. 107.
    Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V et al (2009) Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. Clin Infect Dis 48(5):633–639CrossRefGoogle Scholar
  108. 108.
    Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA (2009) Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101(16):1120–1130CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Simard EP, Pfeiffer RM, Engels EA (2010) Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 170(15):1337–1345CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK et al (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103(9):753–762CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Massad LS, Hessol NA, Darragh TM, Minkoff H, Colie C, Wright RL et al (2017) Cervical cancer incidence after up to 20 years of observation among women with HIV. Int J Cancer 141(8):1561–1565CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Frisch M, Biggar RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92(18):1500–1510CrossRefGoogle Scholar
  113. 113.
    Frisch M, Biggar RJ, Engels EA, Goedert JJ (2001) Association of cancer with AIDS-related immunosuppression in adults. JAMA 285(13):1736–1745CrossRefPubMedGoogle Scholar
  114. 114.
    Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM et al (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 20(12):1645–1654CrossRefPubMedGoogle Scholar
  115. 115.
    Palefsky J (2006) Biology of HPV in HIV infection. Adv Dent Res. 19(1):99–105CrossRefPubMedGoogle Scholar
  116. 116.
    Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL et al (2008) Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123(1):187–194CrossRefGoogle Scholar
  117. 117.
    Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC et al (2008) Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148(10):728–736CrossRefPubMedGoogle Scholar
  118. 118.
    Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV et al (2009) Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23(1):41–50CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Shiels MS, Cole SR, Kirk GD, Poole C (2009) A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 52(5):611–622CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ et al (2011) Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 25(5):691–700CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al (2011) HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomark. PrevCrossRefGoogle Scholar
  122. 122.
    Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC (2012) HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 24(5):506–516CrossRefPubMedPubMedCentralGoogle Scholar
  123. 123.
    Rubinstein PG, Aboulafia DM, Zloza A (2014) Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 28(4):453–465CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    Cote TR, O’Brien TR, Ward JW, Wilson SE, Blattner WA (1995) AIDS and cancer registry linkage: measurement and enhancement of registry completeness. The National AIDS/Cancer match study group. Prev Med 24(4):375–7CrossRefPubMedGoogle Scholar
  125. 125.
    Abraham AG, D’Souza G, Jing Y, Gange SJ, Sterling TR, Silverberg MJ et al (2013) Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr 62(4):405–413CrossRefPubMedPubMedCentralGoogle Scholar
  126. 126.
    Harris TG, Burk RD, Palefsky JM, Massad LS, Bang JY, Anastos K et al (2005) Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 293(12):1471–1476CrossRefPubMedGoogle Scholar
  127. 127.
    Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT et al (2015) Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 162(5):335–344. Scholar
  128. 128.
    Oh JK, Ju YH, Franceschi S, Quint W, Shin HR (2008) Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study. BMC Infect Dis 8:13CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    Xi LF, Koutsky LA, Castle PE, Edelstein ZR, Meyers C, Ho J et al (2009) Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load. Cancer Epidemiol Biomark Prev 18(12):3490–3496CrossRefGoogle Scholar
  130. 130.
    Mzarico E, Gomez-Roig MD, Guirado L, Lorente N, Gonzalez-Bosquet E (2015) Relationship between smoking, HPV infection, and risk of Cervical cancer. Eur J Gynaecol Oncol 36(6):677–680PubMedGoogle Scholar
  131. 131.
    Feng RM, Hu SY, Zhao FH, Zhang R, Zhang X, Wallach AI et al (2017) Role of active and passive smoking in high-risk human papillomavirus infection and cervical intraepithelial neoplasia grade 2 or worse. J. Gynecol. Oncol. 28(5):e47CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Trushin N, Alam S, El-Bayoumy K, Krzeminski J, Amin SG, Gullett J et al (2012) Comparative metabolism of benzo[a]pyrene by human keratinocytes infected with high-risk human papillomavirus types 16 and 18 as episomal or integrated genomes. J. Carcinog. 11:1CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Alam S, Conway MJ, Chen HS, Meyers C (2008) The cigarette smoke carcinogen benzo[a]pyrene enhances human papillomavirus synthesis. J Virol 82(2):1053–1058CrossRefPubMedGoogle Scholar
  134. 134.
    Vernon SD, Hart CE, Reeves WC, Icenogle JP (1993) The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 27(2):133–145CrossRefPubMedGoogle Scholar
  135. 135.
    Arany I, Tyring SK (1998) Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS 9(5):268–271CrossRefPubMedGoogle Scholar
  136. 136.
    Heard I, Palefsky JM, Kazatchkine MD (2004) The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther. 9(1):13–22PubMedGoogle Scholar
  137. 137.
    Guidry JT, Scott RS (2017) The interaction between human papillomavirus and other viruses. Virus Res 231:139–147CrossRefPubMedGoogle Scholar
  138. 138.
    Denny LA, Franceschi S, de Sanjose S, Heard I, Moscicki AB, Palefsky J (2012) Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 30(Suppl 5):F168–F174CrossRefPubMedGoogle Scholar
  139. 139.
    Ghartey J, Kovacs A, Burk RD, Stewart Massad L, Minkoff H, Xie X et al (2014) Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer. J Acquir Immune Defic Syndr 66(3):316–323CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    de Jong MA, Geijtenbeek TB (2009) Human immunodeficiency virus-1 acquisition in genital mucosa: Langerhans cells as key-players. J Intern Med 265(1):18–28CrossRefPubMedGoogle Scholar
  141. 141.
    Herfs M, Hubert P, Moutschen M, Delvenne P (2011) Mucosal junctions: open doors to HPV and HIV infections? Trends Microbiol 19(3):114–120CrossRefPubMedGoogle Scholar
  142. 142.
    Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE et al (2012) Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. Aids 26(17):2211–2222CrossRefPubMedGoogle Scholar
  143. 143.
    Lissouba P, Van de Perre P, Auvert B (2013) Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 89(5):350–356CrossRefPubMedPubMedCentralGoogle Scholar
  144. 144.
    Panel on Antiretroviral Guidelines for Adults and Adolescents (2016) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsGoogle Scholar
  145. 145.
    Palefsky JM (2003) Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 15(5):382–388CrossRefPubMedGoogle Scholar
  146. 146.
    Barbaro G, Barbarini G (2007) HIV infection and cancer in the era of highly active antiretroviral therapy (review). Oncol Rep 17(5):1121–1126PubMedGoogle Scholar
  147. 147.
    Adler DH (2010) The impact of HAART on HPV-related cervical disease. Curr HIV Res 8(7):493–497CrossRefPubMedPubMedCentralGoogle Scholar
  148. 148.
    Bratcher LF, Sahasrabuddhe VV (2010) The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 5:8CrossRefPubMedPubMedCentralGoogle Scholar
  149. 149.
    Rohner E, Sengayi M, Goeieman B, Michelow P, Firnhaber C, Maskew M et al (2017) Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg. South Africa. Int J Cancer. 141(3):488–496PubMedGoogle Scholar
  150. 150.
    World Health Organization. Countries using hpv vaccine 2013. Available from:
  151. 151.
    Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR (2009) Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int. J. Gynecol. cancer Official J Int. Gynecol Cancer Society 19(7):1166–1176CrossRefGoogle Scholar
  152. 152.
    Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al (2010) Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 102(5):325–339CrossRefPubMedGoogle Scholar
  153. 153.
    Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J et al (2016) Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 15(3):367–387PubMedGoogle Scholar
  154. 154.
    Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ et al (2016) Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 63(4):519–527CrossRefPubMedPubMedCentralGoogle Scholar
  155. 155.
    Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K (2016) Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA pediatrics. 170(5):445–452CrossRefPubMedGoogle Scholar
  156. 156.
    Kim J, Bell C, Sun M, Kliewer G, Xu L, McInerney M, et al (2016) Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ: Can. Med. Assoc. J. = J. de l’Assoc. Med.Can. 188(12):E281–8CrossRefPubMedGoogle Scholar
  157. 157.
    Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS et al (2010) Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 55(2):197–204CrossRefPubMedPubMedCentralGoogle Scholar
  158. 158.
    Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA 3rd et al (2012) Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 206(8):1309–1318CrossRefPubMedPubMedCentralGoogle Scholar
  159. 159.
    Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K et al (2013) Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 31(48):5745–5753CrossRefPubMedGoogle Scholar
  160. 160.
    Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N et al (2013) Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 57(5):735–744CrossRefPubMedPubMedCentralGoogle Scholar
  161. 161.
    Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT et al (2014) Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 59(1):127–135CrossRefPubMedPubMedCentralGoogle Scholar
  162. 162.
    Kojic EM, Rana AI, Cu-Uvin S (2016) Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert Rev Vaccines. 15(1):105–117CrossRefPubMedGoogle Scholar
  163. 163.
    Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, et al (2009) Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV medicine association of the infectious diseases society of America, the pediatric infectious diseases society, and the American academy of pediatrics. MMWR Recomm Rep 58(Rr-11):1–166Google Scholar
  164. 164.
    World Health Organization. Human Papillomavirus (HPV) position paper 2017 [Available from:
  165. 165.
    Firnhaber C, Wilkin T (2012) Human papillomavirus vaccines: where do they fit in HIV-infectedi? Curr HIV/AIDS Rep. 9(3):278–286CrossRefPubMedGoogle Scholar
  166. 166.
    Crum-Cianflone NF, Sullivan E (2017) Vaccinations for the HIV-infected adult: a review of the current recommendations. Part I, Infectious diseases and therapyGoogle Scholar
  167. 167.
    Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM (2013) Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 11:227CrossRefPubMedPubMedCentralGoogle Scholar
  168. 168.
    Firnhaber C, Evans D, Friedman-Khalili R, Willliams S, Michelow P, Matlhagela K et al (2011) Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botswana. J Clin Virol 52(3):265–268CrossRefPubMedGoogle Scholar
  169. 169.
    Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156(12):880–91, w312CrossRefPubMedGoogle Scholar
  170. 170.
    Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al (2012)American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA: A Cancer J. for Clinicians 62(3):147–72Google Scholar
  171. 171.
    Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA et al (2015) Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 125(2):330–337CrossRefPubMedGoogle Scholar
  172. 172.
    U.S. Preventive Services Task Force. Draft Recommendation Statement Cervical Cancer: Screening 2017 [Available from:
  173. 173.
    Keller MJ, Burk RD, Massad LS, Eltoum IE, Hessol NA, Castle PE et al (2015) Cervical precancer risk in HIV-infected women who test positive for oncogenic human papillomavirus despite a normal pap test. Clin Infect Dis 61(10):1573–1581CrossRefPubMedPubMedCentralGoogle Scholar
  174. 174.
    Robbins HA, Strickler HD, Massad LS, Pierce CB, Darragh TM, Minkoff H et al (2017) Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach. Aids 31(7):1035–1044CrossRefPubMedPubMedCentralGoogle Scholar
  175. 175.
    Massad LS, Fazzari MJ, Anastos K, Klein RS, Minkoff H, Jamieson DJ et al (2007) Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis. 11(2):90–97CrossRefPubMedGoogle Scholar
  176. 176.
    Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds).MD 2017 SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda, [Available from:
  177. 177.
    Bailey H, Thorne C, Semenenko I, Malyuta R, Tereschenko R, Adeyanova I et al (2012) Cervical screening within HIV care: findings from an HIV-positive cohort in Ukraine. PLoS ONE 7(4):e34706CrossRefPubMedPubMedCentralGoogle Scholar
  178. 178.
    Thorsteinsson K, Ladelund S, Jensen-Fangel S, Katzenstein TL, Johansen IS, Pedersen G et al (2014) Adherence to the cervical cancer screening program in women living with HIV in Denmark: comparison with the general population. BMC Infect Dis 14:256CrossRefPubMedPubMedCentralGoogle Scholar
  179. 179.
    Orang’o O, Liu T, Christoffersen-Deb A, Itsura P, Oguda J, Washington S, et al (2016) Use of VIA, pap smear, or HR-HPV testing in women living with HIV/AIDS for post-treatment cervical cancer screening: same tests, different priorities. AidsGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Medicine, Department of Public Health SciencesPenn State Hershey College of MedicineHersheyUSA

Personalised recommendations